| Literature DB >> 24167374 |
Maryam Boshtam1, Amirnader Emami Razavi, Morteza Pourfarzam, Mohsen Ani, Gholam Ali Naderi, Gholam Basati, Marjan Mansourian, Narges Jafari Dinani, Seddigheh Asgary, Soheila Abdi.
Abstract
INTRODUCTION: Cardioprotective effect of high density lipoprotein (HDL) is, in part, dependent on its related enzyme, paraoxonase 1 (PON1). Fatty acid composition of HDL could affect its size and structure. On the other hand, PON1 activity is directly related to the structure of HDL. This study was designed to investigate the association between serum PON1 activity and fatty acid composition of HDL in healthy men.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24167374 PMCID: PMC3787566 DOI: 10.1155/2013/612035
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Comparison of HDL fatty acid composition between groups.
| Fatty acids | Group 1 | Group 2 | Group 3 |
|
|
|
|---|---|---|---|---|---|---|
| SFA | 42.52 ± 0.42 | 40.48 ± 0.24 | 40.97 ± 0.23 | 0.000 | 0.005 | 0.581 |
| C14:0 (myristic acid) | 0.49 ± 0.02 | 0.43 ± 0.02 | 0.40 ± 0.01 | 0.088 | 0.002 | 0.416 |
| C16:0 (palmitic acid) | 25.94 ± 0.26 | 25.21 ± 0.26 | 25.37 ± 0.30 | 0.154 | 0.300 | 0.924 |
| C18:0 (stearic acid) | 15.78 ± 0.23 | 14.53 ± 0.17 | 14.90 ± 0.16 | 0.000 | 0.004 | 0.354 |
| C20:0 (arachidic acid) | 0.32 ± 0.01 | 0.31 ± 0.02 | 0.30 ± 0.02 | 0.921 | 0.895 | 0.998 |
| UFA | 57.48 ± 2.8 | 59.52 ± 1.6 | 59.03 ± 2.2 | 0.000 | 0.005 | 0.581 |
| MUFA | 10.34 ± 0.19 | 10.58 ± 0.20 | 10.37 ± 0.22 | 0.689 | 0.995 | 0.749 |
| C14:1 (myristoleic acid) | 0.23 ± 0.01 | 0.21 ± 0.01 | 0.21 ± 0.01 | 0.185 | 0.209 | 0.997 |
| C16:1 (palmitoleic acid) | 0.65 ± 0.03 | 0.73 ± 0.05 | 0.64 ± 0.04 | 0.357 | 0.994 | 0.307 |
| C18:1n9c (oleic acid) | 9.6 ± 0.16 | 9.64 ± 0.17 | 9.51 ± 0.18 | 0.748 | 0.975 | 0.867 |
| PUFA | 47.14 ± 0.48 | 48.93 ± 0.29 | 48.66 ± 0.47 | 0.009 | 0.031 | 0.889 |
| C18:3n3 (ALA) | 1.21 ± 0.08 | 1.43 ± 0.09 | 1.29 ± 0.07 | 0.136 | 0.775 | 0.431 |
| C20:3n3 (ETE) | 0.16 ± 0.02 | 0.14 ± 0.02 | 0.11 ± 0.01 | 0.050 | 0.036 | 0.313 |
| C20:5n3 (EPA) | 0.68 ± 0.04 | 0.99 ± 0.17 | 0.59 ± 0.04 | 0.070 | 0.811 | 0.015 |
| C22:6n3 (DHA) | 6.61 ± 0.33 | 6.96 ± 0.33 | 6.15 ± 0.20 | 0.664 | 0.513 | 0.129 |
| C18:2n6c (LA) | 23.85 ± 0.43 | 23.80 ± 0.44 | 24.23 ± 0.54 | 0.997 | 0.834 | 0.800 |
| C20:3n6 (DGLA) | 3.83 ± 0.13 | 3.79 ± 0.19 | 3.66 ± 0.17 | 0.984 | 0.727 | 0.830 |
| C20:4n6 (AA) | 11.60 ± 0.31 | 12.82 ± 0.25 | 13.53 ± 0.39 | 0.026 | 0.000 | 0.217 |
|
| ||||||
| SFA : UFA | 0.74 ± 0.01 | 0.68 ± 0.01 | 0.70 ± 0.01 | 0.000 | 0.004 | 0.562 |
| SFA : MUFA | 4.17 ± 0.08 | 3.88 ± 0.07 | 4.02 ± 0.08 | 0.030 | 0.365 | 0.446 |
| SFA : PUFA | 0.91 ± 0.02 | 0.83 ± 0.01 | 0.85 ± 0.01 | 0.000 | 0.009 | 0.630 |
| Total ω3 | 7.86 ± 0.35 | 8.53 ± 0.38 | 7.25 ± 0.19 | 0.298 | 0.367 | 0.015 |
| Total ω6 | 39.28 ± 0.55 | 40.41 ± 0.44 | 41.41 ± 0.44 | 0.208 | 0.004 | 0.293 |
| ω6 : ω3 ratio | 5.37 ± 0.19 | 5.13 ± 0.22 | 5.91 ± 0.18 | 0.671 | 0.134 | 0.018 |
| AA : EPA | 19.62 ± 1.31 | 20.31 ± 1.65 | 26.64 ± 1.79 | 0.950 | 0.006 | 0.016 |
| EPA : DHA | 0.11 ± 0.01 | 0.16 ± 0.03 | 0.10 ± 0.01 | 0.125 | 0.955 | 0.068 |
ALA: α-linolenic acid, ETE: eicosatrienoic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, LA: linoleic acid, DGLA: dihomo-gamma-linolenic acid, AA: arachidonic acid, SFA: saturated fatty acids, UFA: unsaturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids. Data are expressed as mean ± SE and indicated the percent of fatty acid to total fatty acids.
Bivariate correlations between serum PON1 activity, PON1/HDL-C ratio, and PON1/apo A-I ratio with fatty acid composition of HDL particles in all participants.
| Fatty acids | Serum PON1 |
| PON1/HDL-C ratio |
| PON1/apo A-I ratio |
|
|---|---|---|---|---|---|---|
| SFA | 0.097 | NS | 0.136 | NS | 0.109 | NS |
| C14:0 (myristic acid) | 0.070 | NS | 0.190 | 0.028 | 0.123 | NS |
| C16:0 (palmitic acid) | 0.029 | NS | 0.039 | NS | 0.037 | NS |
| C18:0 (stearic acid) | 0.190 | 0.027 | 0.237 | 0.006 | 0.179 | 0.038 |
| C20:0 (arachidic acid) | −0.064 | NS | 0.026 | NS | −0.004 | NS |
| UFA | −0.097 | NS | −0.136 | NS | −0.109 | NS |
| MUFA | 0.112 | NS | 0.111 | NS | 0.178 | 0.039 |
| C14:1 (myristoleic acid) | −0.024 | NS | 0.034 | NS | 0.044 | NS |
| C16:1 (palmitoleic acid) | 0.141 | NS | 0.157 | NS | 0.197 | 0.022 |
| C18:1 (oleic acid) | 0.102 | NS | 0.095 | NS | 0.164 | NS |
| PUFA | 0.057 | NS | −0.115 | NS | −0.107 | NS |
| C18:3n3 (ALA) | −0.108 | NS | −0.070 | NS | −0.069 | NS |
| C20:3n3 (ETE) | −0.052 | NS | 0.047 | NS | −0.059 | NS |
| C20:5n3 (EPA) | −0.043 | NS | 0.124 | NS | 0.104 | NS |
| C22:6n3 (DHA) | −0.037 | NS | 0.007 | NS | −0.020 | NS |
| C18:2n6c (LA) | −0.100 | NS | −0.106 | NS | −0.133 | NS |
| C20:3n6 (DGLA) | 0.260 | 0.002 | 0.257 | 0.003 | 0.278 | 0.001 |
| C20:4n6 (AA) | 0.038 | NS | −0.075 | NS | −0.010 | NS |
|
| ||||||
| SFA : UFA ratio | 0.097 | NS | 0.136 | NS | 0.109 | NS |
| SFA : MUFA ratio | −0.074 | NS | −0.054 | NS | −0.134 | NS |
| SFA : PUFA ratio | 0.077 | NS | 0.133 | NS | 0.111 | NS |
| Total ω3 fatty acids | −0.047 | NS | 0.022 | NS | −0.010 | NS |
| Total ω6 fatty acids | −0.111 | NS | −0.198 | 0.022 | −0.184 | 0.033 |
| ω6 : ω3 ratio | −0.005 | NS | −0.088 | NS | −0.062 | NS |
| AA : EPA ratio | −0.036 | NS | −0.148 | NS | −0.107 | NS |
| EPA : DHA ratio | 0.054 | NS | 0.067 | NS | 0.084 | NS |
ALA: α-linolenic acid, ETE: eicosatrienoic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, LA: linoleic acid, DGLA: dihomo-gamma-linolenic acid, AA: arachidonic acid, SFA: saturated fatty acids, UFA: unsaturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, NS: not significant.
Bivariate correlations between serum PON1 activity and fatty acid composition of HDL particles between groups.
| Fatty acids (percent of total FA) | Serum PON1 activity | ||
|---|---|---|---|
| Group 1 (HDL ≤ 39) | Group 2 (39 < HDL ≤ 49) | Group 3 (49 < HDL) | |
| SFA | 0.021 | −0.147 | 0.038 |
| C14:0 (myristic acid) | 0.155 | −0.296* | −0.074 |
| C16:0 (palmitic acid) | −0.044 | −0.192 | 0.078 |
| C18:0 (stearic acid) | −0.060 | 0.133 | 0.078 |
| C20:0 (arachidic acid) | 0.006 | −0.315* | −0.106 |
| UFA | −0.021 | 0.147 | −0.038 |
| MUFA | 0.487** | −0.184 | −0.126 |
| C14:1 (myristoleic acid) | 0.106 | −0.342* | −0.168 |
| C16:1 (palmitoleic acid) | 0.457** | −0.058 | −0.203 |
| C18:1 (oleic acid) | 0.474** | −0.189 | −0.099 |
| PUFA | −0.211 | 0.251 | 0.033 |
| C18:3n3 (ALA) | −0.235 | −0.301* | 0.112 |
| C20:3n3 (ETE) | −0.141 | −0.297* | 0.130 |
| C20:5n3 (EPA) | 0.352* | −0.295* | −0.106 |
| C22:6n3 (DHA) | −0.260 | 0.191 | −0.077 |
| C18:2n6c (LA) | −0.332* | −0.145 | 0.201 |
| C20:3n6 (DGLA) | 0.402** | 0.144 | 0.136 |
| C20:4n6 (AA) | 0.222 | 0.425** | −0.250 |
|
| |||
| SFA : UFA ratio | −0.006 | −0.144 | 0.040 |
| SFA : MUFA ratio | −0.414** | 0.082 | 0.165 |
| SFA : PUFA ratio | 0.091 | −0.215 | 0.008 |
| Total ω3 fatty acids | −0.231 | 0.002 | −0.086 |
| Total ω6 fatty acids | −0.037 | 0.177 | 0.074 |
| ω6 : ω3 ratio | 0.190 | −0.054 | 0.127 |
| AA : EPA ratio | −0.227 | 0.205 | 0.047 |
| EPA : DHA ratio | 0.339 | −0.310* | −0.007 |
ALA: α-linolenic acid, ETE: eicosatrienoic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, LA: linoleic acid, DGLA: dihomo-gamma-linolenic acid, AA: arachidonic acid, SFA: saturated fatty acids, UFA: unsaturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids.
(*Significant at the level of 0.05).
(**Significant at the level of 0.01).